



August 31, 2016

## Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif., Aug. 31, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present a corporate overview at two upcoming conferences:

▮ **Credit Suisse Antibody Day**

**Date:** Wednesday, September 7, 2016

**Time:** 9:20 a.m. ET

**Location:** New York, NY

▮ **Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology**

**Date:** Thursday, September 29, 2016

**Time:** 2:30 p.m. ET

**Location:** New York, NY

Live webcasts of both events will be available on the "Events & Presentations" section in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

### **About Xencor, Inc.**

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, nine candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb13676 expected to begin clinical development for B-cell malignancies in 2016. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit [www.xencor.com](http://www.xencor.com).

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/xencor-to-present-at-upcoming-investor-conferences-300320520.html>

SOURCE Xencor, Inc.

News Provided by Acquire Media